Industry Educational Session - Personalising First Line Treatment in Myeloma: Who Benefits Most from Quad Regimens? - Sponsored by Johnson & Johnson
Tracks
-
| Monday, April 20, 2026 |
| 2:30 PM - 3:15 PM |
| Hall 3B, Upper Level |
Details
A symposium focused on tailoring treatment strategies for patients with newly diagnosed multiple myeloma (NDMM). Expert panellists will share multidisciplinary insights on the evolving role of transplant and the decision-making process for quadruplet therapies. Real-world patient cases will be discussed to highlight treatment approaches and de-escalation guidance.
This promotional symposium is fully developed and funded by Johnson & Johnson for UK healthcare professionals only. Johnson & Johnson products will be discussed, and prescribing information and adverse event reporting will be available at the meeting.
Job code: CP-564135 | Date of Preparation: February 2026
Speaker
Prof. Karthik Ramasamy
Professor Of Haematology
Oxford University Hospitals NHS Foundation Trust
Speaker One
Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust – Chair
Dr. Emma Litt
Consultant Haematologist
.
Speaker Two
Consultant Haematologist, Shrewsbury and Telford Hospital NHS Trust
Christine Skeet
Nurse Specialist
.
Speaker Three
Haematology Clinical Nurse Specialist, Royal Derby Hospital
